Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

PHASE1WithdrawnINTERVENTIONAL

Timeline

Start Date

June 30, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

CancerNon-small-cell Lung CancerBreast Cancer

Interventions

DRUG

XL647

Tablets supplied at 50-mg strength administered orally daily

DRUG

XL147

Gelatin capsules supplied at 25-mg and 100-mg strengths administered orally daily

Trial Locations (2)

Memorial Sloan Kettering Cancer Center, New York

South Texas Accelerated Research Therapeutics, San Antonio